



## Trethera Appoints Lynne Rollins as new Chief Financial Officer

**Beverly Hills, CA, - 21 July 2016** – Trethera, a biotechnology company focused on the discovery and development of innovative small molecules for the treatment of hematological and solid tumors today announced the appointment of Lynne Rollins as its new Chief Financial Officer (CFO). The appointment is effective immediately.

Lynne brings over 35 years' of experience in the healthcare industry across finance, strategic planning and business development. Following senior positions at Baxter Healthcare Corporation, Lynne has advised over 30 startup medical device and biopharmaceutical companies including HighLife Medical, Syndax Pharmaceuticals and Calixa Therapeutics. Lynne has a B.S. in Finance from California State University and a MBA from Pepperdine University.

**Dr Johanna Holldack, CEO of Trethera commented:**

*“Lynne brings to Trethera a wealth of management experience and a proven ability to raise and manage capital. Her experience across a wide range of early stage companies will be instrumental as Trethera continues to grow.”*

*“Our development of innovative therapeutics in the oncology field will see us moving our drug candidates into the clinic. As we evolve into a clinical stage company, strong leadership across the Company is essential.”*

**Lynne Rollins, newly appointed CFO, added:**

*“Trethera is at a transformative stage, with TRE-515 advancing through preclinical development in both hematological and solid tumor cancers. The Company's stage of development and quality of the science behind the portfolio was a big draw for me to join up. I look forward to working with Johanna and the team.”*

Trethera is discovering and developing innovative small molecules that control DNA replication and integrity for the treatment of hematological and solid tumors. The Company's proprietary technology platform is based on a deep understanding of the regulatory checkpoints in the complex system of nucleotide metabolism. The Company is building a pipeline of oncology products by harnessing this technology platform.

**-End-**

**For more information, please contact:**

**Trethera**  
Dr. Johanna Holldack, CEO

**Tel: +1 310 997 278**  
jholldack@trethera.com

**Instinctif Partners**  
Dr. Christelle Kerouedan

**Tel: +44 (0)20 7457 2020**  
trethera@instinctif.com

### NOTES TO EDITORS

#### About Trethera

Trethera is a biotechnology company focused on the discovery and development of innovative small molecules that precisely control nucleotide metabolism and DNA replication and integrity for the treatment of malignant diseases.

The Company is building a pipeline of oncology products by harnessing its proprietary technology platform which is based on regulatory checkpoints in the complex system of nucleotide metabolism.



Trethera's lead compound DI-87 (TRE-515) is advancing through pre-clinical development with programs in both Leukemia and Solid Tumors. It is an oral small molecule inhibitor of Deoxycytidine Kinase, an important enzyme implicated in cancer cell proliferation. TRE-515 is being developed as a combination therapy and it is anticipated that the first clinical trial will commence in the second half of 2017.

The Company has a strong and growing patent position and an exclusive license from UCLA for patents relating to its platform and Deoxycytidine Kinase Inhibitors. The research behind the technology and products has received competitive grants and departmental funds totaling millions of dollars over the past eight years.

Trethera is located in California, U.S.

For more information, please visit the website: [www.trethera.com](http://www.trethera.com)